Related Experiment Video
Updated: Jun 4, 2025
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
15.7K
Prognostic Biomarkers in Evolving Melanoma Immunotherapy
Robin Reschke1,2, Alexander H Enk3, Jessica C Hassel3,4
1Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg University, NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany. RobinNiklas.Reschke@med.uni-heidelberg.de.
American Journal of Clinical Dermatology
|December 20, 2024
Summary
Identifying reliable biomarkers is crucial for effective melanoma immunotherapy. This review covers established and emerging markers like PD-L1, TMB, and ctDNA to personalize skin cancer treatment.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Melanoma immunotherapy has advanced treatment but shows variable patient responses.
- Reliable biomarkers are needed to guide personalized treatment decisions for melanoma patients.
Purpose of the Study:
- To review established and emerging biomarkers for melanoma immunotherapy.
- To discuss the role of biomarkers in personalizing treatment and future research directions.
Main Methods:
- Literature review of key biomarkers in melanoma immunotherapy.
- Exploration of established markers: PD-L1 expression, tumor mutational burden (TMB), gene expression profiles (GEPs).
- Investigation of emerging markers: LAG-3 expression, immune cell phenotyping, gut microbiota, circulating tumor DNA (ctDNA).
Main Results:
- PD-L1, TMB, and GEPs are key established biomarkers.
- Emerging biomarkers like ctDNA show promise, potentially predicting response to agents like tebentafusp.
- Biomarkers are essential for tailoring immunotherapy and guiding future research, including neoadjuvant strategies.
Conclusions:
- Biomarkers are critical for optimizing melanoma immunotherapy outcomes.
- Emerging biomarkers like ctDNA offer new avenues for treatment personalization.
- Future research should focus on integrating these biomarkers into clinical practice and exploring novel therapeutic approaches.
Related Concept Videos
01:27Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
01:30Skin Cancer
3.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.1K